Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer’s disease

Fig. 1

Regulation of monocyte subsets and a slight improvement in memory function following chronic MDP administration over 6 months (high frequency) in APP mice. a Representative timeline of chronic MDP administration over 6 months (high frequency) in APP mice, n = 10 mice per group. b Percentage of blood inflammatory Ly6Chi monocytes at two time points (3 and 6 months) following chronic MDP administration over 6 months (high frequency) in APP mice. Data are expressed as the means ± SEM; ***P < or = 0.0004 vs. APP vehicle in 3 months, ###P < or = 0.0004 vs. APP vehicle in 6 months. c Percentage of blood Ly6Clow patrolling monocytes at two time points (3 and 6 months) following chronic MDP administration over 6 months (high frequency) in APP mice. Data are expressed as the means ± SEM; ***P < or = 0.0004 vs. APP-MDP in 3 months, ###P < or = 0.0004 vs. APP-MDP in 6 months. d The total number of errors made on day 1 (D1), day 2 (D2), and day 3 (D3) in APP-MDP and APP-vehicle groups in learning performance in position habit acquisition at the two time points (3 and 6 months). Data analyzed using two-way ANOVA for the time points and treatments. e The total number of errors made on day 1 (D1), day 2 (D2), and day 3 (D3) in APP-MDP and APP-vehicle groups in learning performance in reversal learning training at the two time points (3 and 6 months). Data analyzed using two-way ANOVA for the time points and treatments. f Percentage of mice in APP-MDP and APP-vehicle groups made errorless trials in day 1 in reversal learning training at the two time points (3 and 6 months). g Average of total errors in APP-MDP and APP-vehicle groups in learning performance in reversal learning training at the two time points (3 and 6 months). Data analyzed using two-way ANOVA for the time points and treatments

Back to article page